Clinical study on development of resistance and cross resistance of respiratory pathogens to ofloxacin (OFLX) and ciprofloxacin (CPFX) was carried out in 11 patients with cystic fibrosis, 1 patient with chronic respiratory tract infection having congenital hypogammaglobulinemia and 1 patient with bronchopneumonia secondary to controlled respiration because of spinal cord injury.
Causative organisms isolated from the expectorated sputum were 13 strains of mucoid
Pseudomonas aeruginosa, 6 of rough
P. aeruginosa and each one of
P. maltophilia, Serratia liquefaciens and
Klebsiella oxytoca.
Determination of minimum inhibitory concentrations (MICs) of OFLX and CPFX was performed by using agar plate method for 10 colonies of each isolate.
OFLX was administered to a total of 6 cases infected with
P. aeruginosa. MICs of OFLX against
P. aeruginosa increased 4 time or more in two cases in comparison with initial values and MICs of CPFX increased 4 times or more in same strains simultaneously.
In another case, MIC of OFLX was not changed, however MIC of COFX increased 4 times afterwards.
MICs of OFLX against
S. liquefaciens and
K. oxytoca in one case increased, MICs of CPFX against both strains also increased significantly. Two patients were treated with CPFX alone and 6 were treated with CPFX and other antibiotics in combination.
MIC of CPFX against mucoid
P. aeruginosa in case No.6 increased and MIC of OFLX against same strain increased. In case No.14, both mucoid and rough
P. aeruginosa became resistant to CPFX and OFLX after CPFX treatment.
It is considered that among new quinolones, cross resistance could be developed easily, however there is no strains which become highly resistant to both OFLX and CPFX.
View full abstract